Company intelligence / Profile preview

IsomAb

Cambridge, England, United Kingdomisomab.bio ↗

Ownership: Private
Development stage: Preclinical

Overview

IsomAb is advancing its lead program, ISM-001, a first-in-class humanized monoclonal antibody targeting VEGF-A165b for the treatment of peripheral artery disease, especially in patients with type 2 diabetes and chronic limb-threatening ischemia. The company has completed candidate nomination and is conducting preclinical studies to support IND/CTA filing for first-in-human clinical trials. No clinical results have been reported yet.

Therapeutic areas: Cardiovascular
Modalities: Monoclonal antibody
Industry: Biotech

Drug pipeline

1 asset

ISM-001

Preclinical

Partnerships

Catalent (strategic collaboration for process development and clinical trial supply)Pfizer Ignite (strategic collaboration to accelerate preclinical and IND-enabling studies for ISM‑001)

Beyond the preview

Go deeper on IsomAb.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IsomAb.